Market Intelligence, Clinical Progress, and High-Purity Reagents for Laminopathy and Progeria Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LMNA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LMNA Recombinant Protein (Wild-Type & Mutant) High purity (>90%), Endotoxin <1.0 EU/μg. Sequence Verified. |
View LMNA Products |
| Gene Delivery | LMNA Promise-ORF / Lentivirus Full-length ORF and disease mutants (e.g., G608G) for stable cell line generation. |
View LMNA Products |
| Benchmark Ab | Anti-LMNA Recombinant Antibody Recombinant positive control antibody for Western Blot, ICC/IF, and ELISA validation. |
View LMNA Products |
| Validator | LMNA siRNA Set Target-specific siRNA pool for knockdown verification in functional assays. |
View LMNA Products |
| Related Target A | ZMPSTE24 Zinc metallopeptidase required for proteolytic processing of prelamin A to mature lamin A. |
View ZMPSTE24 Products |
| Related Target B | LMNB1 Lamin B1, crucial for nuclear envelope structural integrity; key control for nuclear lamina selectivity screening. |
View LMNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing Wild-Type Lamin A from Mutant Progerin | Recombinant Wild-Type LMNA and deletion mutant (Progerin) proteins available with verified sequence identity via LC-MS/MS. |
| Nuclear Envelope Localization Validation | High-titer Lentivirus expressing GFP-tagged LMNA/Progerin for real-time live-cell imaging and high-content screening. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated positive controls included in the catalog. |
| False Positives in Gene Editing | Sequence-verified locus-specific genomic validation tools and control siRNAs. |
Live LMNA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of LMNA (Lamin A/C) is undergoing a major paradigm shift. Historically managed with symptomatic or downstream small-molecule treatments (such as farnesyltransferase inhibitors like Lonafarnib), the next generation of LMNA-targeted therapeutics focuses heavily on genetic medicines. The emergence of CRISPR/Cas9, base editors, and antisense oligonucleotides (ASOs) has opened up direct avenues to correct or silence the pathogenic LMNA mutations responsible for Hutchinson-Gilford Progeria Syndrome (HGPS), Emery-Dreifuss muscular dystrophy (EDMD), and dilated cardiomyopathy (DCM).
As gene-editing technologies advance into clinical phases, drug developers face rigorous demands for high-fidelity assay reagents. Specifically, distinguishing therapeutic effects on mutated isoforms (such as Progerin) versus normal Lamin A/C requires highly specific antibodies and sequence-verified recombinant proteins to validate target engagement and avoid off-target toxicities in cardiac and skeletal tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Base Editing / CRISPR | Beam Therapeutics, Verve Therapeutics | HGPS (Progeria), Dilated Cardiomyopathy | Lentivirus-driven mutation-specific cell lines to validate gene correction efficiency. |
| Antisense Oligonucleotides (ASOs) | Sarepta Therapeutics, Academic Consortia | Laminopathies, EDMD | High-purity WT and mutant LMNA proteins for competitive binding assays and RNA-protein interaction analysis. |
| Small Molecules | Eiger BioSciences, Novartis | Progeria, Cardiomyopathy, Lipodystrophy | Recombinant ZMPSTE24 and prelamin A intermediates for enzymatic inhibition assays. |